9 results about "Eye disorder" patented technology

The invention provides methods of treating an eye disorder and compositions for use therein, the methods comprising applying a crosslinkable liquid composition onto an anterior corneal surface of said eye using a mold; crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a crosslinked composition on the anterior corneal surface of the eye; and correcting the curvature of the crosslinked composition.

A method of treating an eye disorder in a patient that may include administering a medicament to the patient with a prefilled syringe, wherein the administration of the medicament with the prefilled syringe is configured to treat the eye disorder and decrease a rate of likelihood of an ocular infection to the patient's eye.

A system and method are presented for measuring near point of convergence (NPC) and / or convergence recovery point (CRP) of patient's eyes. The system comprises: an eye tracking device configured and operable to provide measured eye-related data of the eyes being indicative of visual axes of the eyes associated with eyes' vergence during a measurement session; a target tracking device, being calibrated with respect to the eye tracking device, and being configured and operable to monitor distances from the eyes to a moving target, onto which the eyes are required to be focused during said measurement session, and to provide measured target-related data indicative of a relative target location relative to the eyes; and a memory and processing circuitry configured and operable to analyze the measured eye-related data and the measured target-related data and determine a relation between a change in the data indicative of the visual axes and data indicative of a change of said distance to the target during movement of said target during the measurement session, and to extract data indicative of said NPC and / or CRP from said relation.

Provided herein are methods of treating various eye disorders, including, for example, wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR), using an anti-VEGF therapy, such as an anti-VEGF antibody conjugate.

The present invention relates to a method for treating or preventing an angiogenic eye disorder, in a subject in need thereof, comprising administering to an eye of the subject, a single initial dose of about 8 mg or more of a VEGF antagonist, followed by one or more secondary doses of about 8 mg or more of the VEGF antagonist, followed by one or more tertiary doses of about 8 mg or more of the VEGF antagonist; wherein each secondary dose is administered about 2 to 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered about 4, 8 or 12 weeks after the immediately preceding dose.

This disclosure generally relates to the field of ophthalmic therapies, and more particularly to the treatment of various eye diseases and conditions by the non-surgical administration into a subject's eye of a pharmacological composition described herein containing a plasma kallikrein inhibitor. Avoralstat is included among the plasma kallikrein inhibitors. The compositions and methods include the administration of a plasma kallikrein inhibitor into the suprachoroidal space (SCS) of the eye.

This specification describes a processable composition comprising at least one moiety that can be processed in free form. This specification also describes compositions and methods for treating eye diseases or disorders, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior ocular inflammation, anterior ocular inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods include steroids and prostaglandins that demonstrate anti-inflammatory activity, intraocular pressure (IOP) reduction, and / or other desirable activities. The compositions are injected into the eye to provide therapeutic benefits to patients suffering from eye disorders.

The present disclosure relates to devices for treating eye disorders, such as macular degeneration, with electromagnetic pulses and / or photobiomodulation. Examples of the devices, include wearable, portable, or mobile devices, which include a light source and a pulsed electromagnetic field emitter that are connected to or capable of connecting to a frame, such as an eye wear. Benefits of the devices disclosed herein can include a device for treating eye disorders, which can be self-administered by a patient or subject at home, at work, or during travel.